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BACKGROUND: Chloride channel accessory 1 (CLCA1) is a CLCA protein that plays a functional role in regulating the differentiation
and proliferation of colorectal cancer (CRC) cells. Here we investigated the relationship between the level of CLCA1 and the prognosis
of CRC. METHODS: First, the level of CLCA1 was detected quantitatively in normal and cancerous colonic epithelial tissues with immu-
nohistochemistry. Next, the correlations between CLCA1 expression, pathological tumor features, and the overall survival rate of
patients was analyzed. Finally, 3 publicly available data sets from the Gene Expression Omnibus were examined: normal CRC versus
early CRC (GSE4107), primary CRC versus metastatic lesions (GSE28702), and low chromosomal instability versus high chromosomal
instability (GSE30540). RESULTS: The expression of CLCA1 was decreased markedly in tumor specimens. CLCA1 expression was cor-
related significantly with the histological grade (P<.01) and lymph node metastasis (P< .01). A significantly poorer overall survival
rate was found in patients with low levels of CLCA1 expression versus those with high expression levels (P<.05). The results con-
firmed that the low expression of CLCA1 in CRC was highly associated with tumorigenesis, metastasis, and high chromosomal instabil-
ity. In addition, the loss of CLCA1 disrupted the differentiation of human colon adenocarcinoma cells (Caco-2) in vitro.
CONCLUSIONS: These findings suggest that CLCA1 levels may be a potential predictor of prognosis in primary human CRC. Low
expression of CLCA1 predicts disease recurrence and lower survival, and this has implications for the selection of patients most likely
to need and benefit from adjuvant chemotherapy. Cancer 2015;121:1570-80. VC 2015 The Authors. Cancer published by Wiley Periodi-
cals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited,
the use is non-commercial and no modifications or adaptations are made.
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INTRODUCTION
The chloride channel accessory (CLCA) family (also called the calcium-sensitive chloride conductance protein family)
comprises 4 genes in humans and at least 6 genes in mice.1-5 All members of the CLCA family map to the same region on
chromosome 1p31-p22 and share a high degree of homology in size, sequence, and predicted structure, but they differ sig-
nificantly in their tissue distribution. The human genome encodes 3 functional CLCA proteins, including CLCA1,
CLCA2, and CLCA4. CLCA2 has been identified to be a p53-inducible inhibitor of cell proliferation and to be a marker
of differentiated epithelium that is downregulated with tumor progression.1,6 CLCA4 is downregulated in breast cancer
cells, and low expression of CLCA4 indicates a poor prognosis for patients with breast cancer.7 CLCA4 and CLCA1 are
expressed in intestinal epithelium.3,8-10 CLCA1 and CLCA4 may function as tumor suppressors and are associated nega-
tively with tumorigenicity.11We have shown that CLCA1 contributes to differentiation and proliferation inhibition in co-
lon cell lines,10 but the role of CLCA1 in the prognosis of patients with colorectal cancer (CRC) remains unclear.
In cancer progression, individual cells undergo complex and important interactions with the extracellular environ-
ment through transmembrane signal transduction. These interactions regulate cancer cell proliferation, invasion, and me-
tastasis. Ion channels are a crucial first step in this process, and they play emerging roles in carcinogenesis and tumor
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progression.11 For example, activation of the chloride cur-
rent through specialized volume-regulated anion channels
in response to cell swelling is one of the major mecha-
nisms by which cells restore their volume after hypo-
osmotic stress (regulatory volume decrease, RVD).12 This
is important because there is a direct link between the apo-
ptotic resistance conferred by the antiapoptotic Bcl-2 pro-
tein and the strengthening of RVD capability due to
upregulation of the chloride current and swelling.13
Therefore, further investigations will elucidate important
roles for ion channels in cancer development and progres-
sion and potentially establish ion channels as effective dis-
criminative markers and therapeutic targets.14
We have reported that CLCA1 is expressed in differ-
entiated, growth-arrested mammalian epithelial cells but is
downregulated during tumor progression.10 We have iden-
tified CLCA1 as a regulator of the transition from prolifera-
tion to differentiation in Caco-2 cells. In this study, we
have determined further that the expression of CLCA1 in
human CRC intestinal tissue is associated with the primary
tumor status (the degree of invasion of the intestinal wall),
lymph node metastases, and the overall survival rate.
CLCA1 also is correlated closely with tumor suppressor
p53 and E-cadherin, which has been determined to influ-
ence the prognosis of CRC.15-18 Our findings suggest that
the expression level of CLCA1 may predict disease relapse
and outcomes for patients with CRC.
MATERIAL AND METHODS
Patients
Thirty-six patients were diagnosed with CRC (26 with co-
lon cancer and 10 with rectal cancer; Table 1), which was
classified with the International Union Against Cancer
TNM staging system and the Dukes staging system. All
patients underwent surgical resection of their tumors at
the 309th Hospital in Beijing, China. Ethical approval for
the study was granted by the 309th Hospital’s ethics com-
mittee. Informed written consent was obtained from all
participants involved in the study.
The key clinical characteristics of the patients are
summarized in Table 1. Normal specimens were obtained
from 2 sources: 2 samples came from normal colon tissue
of noncancer patients, and 4 samples were obtained from
adjacent, grossly normal-appearing tissue taken at least
10 cm away from the cancer. This was in accordance with
other research.19 All tumor samples were obtained from
surgical resection. After surgical resection of their tumors,
patients were followed up with clinical examinations, ab-
dominal ultrasonography or abdominal computer tomog-
raphy scans, and carcinoembryonic antigen measurements
every 6 months for the first 5 years. Thereafter, these inves-
tigations were performed annually until 5 years after the
initial treatment. The patients who died as a result of any
postoperative complications or non–cancer-related diseases
were excluded from the survival analysis. A patient with a
family history suggestive of hereditary nonpolyposis colon
cancer syndrome was excluded. None of the patients
included in this study had chemotherapy or radiotherapy
before surgery. In all, 36 CRC patients were included in
the survival analysis. Adjuvant chemotherapy was given to
all CRC patients except those with stage I disease (cancer
had not invaded the outermost layers of the colon or rec-
tum and had not spread to lymph nodes or distant sites).
The mFOLFOX6 chemotherapy regimen consisted of a 2-
hour intravenous infusion of oxaliplatin (85 mg/m2) and
folinic acid (400 mg/m2), which was followed by an intra-
venous bolus injection of 5-fluorouracil (400 mg/m2) plus
a 46-hour intravenous infusion of 5-fluorouracil
(2400 mg/m2); this was repeated every 2 weeks. After 4
cycles of therapy, all lesions were assessed with computer
tomography.
Clinical Follow-Up
All patients were prospectively followed up according to
the schedule described previously. The mean follow-up
time in this study was 46 months (range, 7-52 months).
The status of each patient was determined at the date of
the last follow-up or at the end of a 5-year follow-up pe-
riod, and if they were deceased, the cause of death was
TABLE 1. Clinical Characteristics of Patients With
Colorectal Cancer
Variable n (%)
Patients 36 (100)
Men 25 (69.4)
Women 11 (30.6)
Primary tumor status
T1 7 (19.4)
T2 5 (13.9)
T3 16 (44.4)
T4 8 (22.2)
Primary lymph node status
N0 25 (69.4)
N1/N2 11 (30.6)
Dukes staging
A 7 (19.4)
B 18 (50)
C 5 (13.9)
D 6 (16.7)
Histological grade
I 10 (27.8)
II 13 (36.1)
III 13 (36.1)
Metastasis
Local 4 (11.1)
Liver 2 (5.6)
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ascertained from the medical records and/or death certifi-
cate information. At the initial diagnosis, 6 patients with
CRC had metastases.
Histology and Colon Cancer Staging
Resected tumors were obtained immediately after surgical
resection and were fixed in 10% pH-neutral formalin and
embedded in paraffin. Paraffin-embedded tissue sections
(5 mm thick) were cut serially and used for hematoxylin-
eosin staining and immunohistochemical analysis. The
patients were staged according to the International Union
Against Cancer TNM staging system and the Dukes stag-
ing system (Table 1).20 The Dukes staging system (used
for colon cancer staging originally) was defined as follows:
(A) tumor in the mucosa, (B) tumor in the muscle layer,
(C) involvement of lymph nodes, and (D) distant metas-
tases. Tumors were classified also by their degree of histo-
logical differentiation: (well differentiated [I]),
moderately differentiated [II], or poorly differentiated
[III]), the presence or absence of perineural invasion, the
presence or absence of venous emboli, and the number of
lymph nodes involved by the tumor.
Immunohistochemistry
After paraffin embedding, the tissue was cut into 5-mm-
thick sections and mounted onto Superfrost Plus slides.
The immunohistochemistry was performed on Leica
Bond Max and included dewaxing and heat-induced epi-
tope retrieval with Epitope Retrieval 1 (Leica Biosystems)
at 100C. Peroxidase block from the Bond Refine Detec-
tion System was used. The primary antibody CLCA1
(polyclone; Santa Cruz) was applied at a 1:100 dilution
for 30 minutes at room temperature. The staining was
completed with the Bond Polymer Refine Detection sys-
tem. The Bond Polymer Refine Detection system con-
tained a peroxide block, post primary, a polymer reagent,
3,30-diaminobenzidine chromogen, and a hematoxylin
counterstain (Leica Biosystems). p53, E-cadherin, phos-
phatase and tensin homolog (PTEN), and Ki-67 expres-
sion was evaluated according to the proportion of
positively stained tumor cells.
Knockdown of CLCA1 and Western Blotting
Caco-2 cells (53105; American Type Culture Collection)
were cultured on collagen I–precoated 6-well plates for
the indicated time. Cells were lysed with a cell lysis buffer
(Sigma-Aldrich) and a protease inhibitor cocktail
(Thermo Scientific) for western blot analysis. Knockdown
of CLCA1 in Caco-2 cells has been described previ-
ously.10 Briefly, a stealth RNAi small interfering RNA
(siRNA) duplex with sense-strand sequences (50-
CAAUGCUACCCUGCCUCC AAUUACA-30; Invitro-
gen, United Kingdom) was used to specifically target the
CLCA1 gene. Caco-2 cells were transfected with Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s
protocol with a final siRNA concentration of 150 nM.
Nontargeting negative control siRNA was used for non–
sequence-specific effects of these molecules. After 72
hours, cells were lysed for western blot analysis. The pri-
mary antibodies used for western blotting included anti-
CLCA1 (1:1000; Santa Cruz), anti–E-cadherin (1:5000;
BD), anti–intestinal alkaline phosphatase (anti-ALPI;
1:2000, Novus), and anti–glyceraldehyde 3-phosphate
dehydrogenase (1:50,000; Santa Cruz). Membranes were
incubated with the relevant primary antibodies overnight
at 4C. A secondary antibody with horseradish peroxidase
(1:5000; Sigma-Aldrich, United Kingdom) was used, and
the immunoblots were detected with WesternBright ECL
(AGTC Bioproducts).
Quantitative Analysis
Slides were assessed with light microscopy. All slides were
analyzed by 2 independent observers (L.C. and J.P.) who
were blinded to the clinical data. For each colon carci-
noma, staining was evaluated on separate slides, which
included the core and the invasive edge of the tumor,
respectively. Slides were examined at 3400 (403 objec-
tive and 103 ocular) and were analyzed via the counting
of all cells present in them (at least 5000 cells). All of the
slides were reviewed independently by each researcher
twice. Discrepancies between investigators (<10% of the
cases) required a third joint observation with a conclusive
agreement.21 The expression of CLCA1 was scored as the
ratio of the number of positive cells to the total number of
cells (stained cells/total number evaluated). The samples
were considered CLCA1-positive if any positive staining
was detected unless there were only rare, isolated single
cells. To translate a continuous variable of CLCA1 expres-
sion into a clinical decision, it is necessary to stratify
patients into 2 groups that may have different prognoses.
Currently, there is no standard method or standard soft-
ware for biomarker cutoff determination.22 However, our
approach was to use X-tile 3.6 plot software (developed by
Camp et al23), which provides a single, global assessment
of every possible way of dividing a population into low-,
medium-, and high-level marker expression. Using an X-
tile plot, we determined the significant, optimal cut point
to be 30% (P5 .0224). Therefore, we used 30% CLCA1
positive staining as a cutoff value to unequivocally catego-
rize cases into 2 groups: high expression of CLCA1
(>30% of cells stained) and low expression of CLCA1
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(none or 30% of cells stained). This was in accordance
with other research.21,24
Microarray Data Analysis
The microarray data sources were obtained from the Gene
Expression Omnibus (GEO).25 Three data sets (series
accession numbers GSE4107, GSE28702, and
GSE30540) were not subjected to any additional normal-
ization because all had been normalized when we obtained
them.19 In GSE4107, early CRC specimens (n5 12) and
adjacent, grossly normal-appearing tissue (n5 10) at least
8 cm away were collected routinely and archived from
patients undergoing colorectal resection at the Singapore
General Hospital.19 In the GSE28702 study, 83 patients
with unresectable CRC, including 56 patients with pri-
mary CRC and 27 patients with metastatic lesions in the
liver (23 tumors), lungs (1 tumor), and peritoneum (3
tumors), were recruited from April 2007 to December
2010 at Teikyo University Hospital and Gifu University
Hospital.26 All CRC samples were obtained before
mFOLFOX6 therapy. GSE30540 included 25 chromo-
somal instability–high (CIN-high) CRC patients and 10
chromosomal instability–low (CIN-low) CRC patients.27
We analyzed the expression of CLCA1 in these published
microarray data sets with the GEO software. The identity
of genes across microarray data sets was established with
public annotations primarily based on Unigene.28
Statistical Analysis
Statistical analysis was performed with Excel and Prism.
The equality of group means and comparisons between
proportions were analyzed with an unpaired Student t test
and chi-square test, respectively. Univariate statistical
analysis was performed with a log-rank test (Mantel-Cox).
X-tile 3.6.1 plot software (http://medicine.yale.edu/lab/
rimm/research/software.aspx) was used to determine the
cutoff point of the CLCA1 expression level for separating
all patients into 2 groups to examine the impact of
CLCA1 expression on prognosis. The curves were plotted
with the product-limit method (Kaplan-Meier) and were
analyzed with Spearman correlation coefficients and Wil-
coxon tests for all survival analyses. For covariates retained
in the model, relative hazards with 95% confidence inter-
vals were estimated. Differences with a P value of .05 or
less were considered to be statistically significant.
RESULTS
Patients and Tumors
The characteristics of the 36 CRC patients in the study
cohort are shown in Table 1. There were 11 women
(30.6%) and 25 men (69.4%). The median age was 55.5
years with a range of 25 to 80 years. In terms of the ana-
tomical location of the tumors, 15 (41.7%) were in the
ascending colon, 2 (5.6%) were in the transverse colon, 3
(8.3%) were in the left colon, 6 (16.7%) were in the sig-
moid colon, and 10 (27.8%) were in the rectum. Twenty-
six patients (72.2%) had moderately or poorly differenti-
ated tumors, with the remaining 10 (27.8%) having well-
differentiated cancers. The Dukes staging was as follows:
(A) 7 or 19.4%, (B) 18 or 50%, (C) 5 or 13.9%, and (D)
6 or 16.7%.
Expression of CLCA1 and Clinical Grades
of CRCs
The level of expression of CLCA1 with respect to tumor
staging is shown in Table 2. There was a high level of
CLCA1 expression in normal colonic epithelium in stark
contrast to the tumor tissue (Fig. 1A). The mean percent-
age of CLCA1-positive cells was 88% in the normal sam-
ples (n5 6) and 54% in the tumor samples (n5 36). In
addition, the expression pattern of CLCA1 was predomi-
nantly membranous and cytoplasmic in normal colonic
epithelium, but this pattern was altered in the tumor area,
which showed an absence of cytoplasmic and/or membra-
nous staining (Fig. 1A). Furthermore, we analyzed the
relationship between the level of expression of CLCA1
and the primary tumor status (T1-T4), lymph nodes sta-
tus (N0 or N1/N2), Dukes stage (A-D), and histological
grade (well, moderately, or poorly differentiated). This
analysis showed that the CLCA1 expression in noncancer-
ous control mucosa samples was significantly higher than
that in samples with tumors. There also was a significant
difference between normal tissue and early CRC tissue
(T1, P< .05). In addition, in the more advanced tumor
stages (T3 and T4), the expression of CLCA1 was reduced
in comparison with earlier stage tumors (T1/T2 vs T3/
T4, P< .01; Fig. 1B and Table 2). Furthermore, CLCA1
expression levels in primary tumors were reduced signifi-
cantly when the patients had positive lymph nodes (N1/
N2, P< .01; Fig. 1C). In Dukes stage A and B tumors,
there was much higher expression of CLCA1 in compari-
son with Dukes stage C and D tumors (P< .01; Fig. 1D
and Table 2). An analysis by histological grades also
showed that the expression of CLCA1 was reduced signifi-
cantly in poorly differentiated tumors versus well-
differentiated tumor (P< .01; Fig. 1E and Table 2). Our
data indicate that low CLCA1 expression levels are associ-
ated with an advanced tumor stage, a less differentiated
tumor histological grade, and metastases in regional
lymph nodes.
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Reduced Expression of CLCA1 Is an Indicator of
the Likelihood of Disease Relapse and Poorer
Survival
The median disease-free survival (DFS) for all patients
was 34.5 months. The postoperative median DFS for
patients with high expression of CLCA1 was 40 months,
whereas that of patients with low CLCA1 expression was
23 months. CRC patients with reduced CLCA1 expres-
sion had a higher risk of disease relapse and death than
patients with high CLCA1 expression (P< .01; Table
2). Kaplan-Meier analysis was used to evaluate the corre-
lation between the survival of patients with CRC and the
level of expression of CLCA1. Patients were divided into
2 groups: CRC patients with high CLCA1 expression
(>30%) and those with low CLCA1 expression
(30%). Our data showed that the DFS for CRC
patients whose tumors had preserved CLCA1 expression
was significantly higher than the DFS for patients with
low CLCA1 expression (P< .05; Fig. 2A). Kaplan-
Meier analysis was also performed with stratification by
the characteristics of the primary tumor and lymph node
metastases. We classified patients into groups with T1/
T2 (n5 12) and T3/T4 tumors (n5 24) because of the
case number and better prognosis with T1/T2 tumors
versus T3/T4 tumors29 and with lymph node–negative
tumors versus lymph node–positive tumors. Our results
also showed that the primary tumor stage was correlated
with the DFS of CRC patients. The DFS of patients
with T3/T4 tumors was reduced significantly in compar-
ison with the DFS of patients with T1/T2 tumors
(P< .05; Fig. 2B).
However, the lymph node status (N0 vs N1/N2)
with respect to the DFS of this group of CRC patients
showed a difference with a P value of .06 (Fig. 2C). Ki-67
has been studied as a prognosticator for CRC,30 but we
showed that there was no significant association between
the expression levels of Ki-67 and the survival of CRC
patients (Fig. 2D). Overall, our results demonstrated that
the CLCA1 expression level was a prognostic factor for
the survival of patients with CRC in the univariate analy-
sis. Patients with CRC characterized by high levels of
CLCA1 expression had a favorable prognosis, whereas
patients with CRC with low CLCA1 expression had a
poorer survival rate.
Correlation Between CLCA1 and PTEN, p53,
E-Cadherin, and Ki-67 in CRC Patients
Abnormal expression or mutations of PTEN and p53, E-
cadherin, and Ki-67 are associated with a poor prognosis
for patients with CRC.15,18,30-32 We also checked theTA
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expression of PTEN, p53, Ki-67, and E-cadherin in
patients and compared the relationship between expres-
sion levels of CLCA1 and these 4 tumor-associated genes.
We found that 16 of 28 CRC patients (57%) had high
expression (>50% score) of Ki-67 cancer cells. However,
no correlation was found between the levels of CLCA1
Figure 1. The expression of CLCA1 correlates with tumor stages, histological grades, and lymph node metastasis in colorectal can-
cer. (A) CLCA1 in normal colonic tissue showed (i) preservation of high levels of expression (brown) on cell membranes and in
the cytoplasm, (ii) reduced expression on membranes and in the cytoplasm in colon cancer tissue, (iii) reduced expression in
cytoplasm only in colon cancer tissue, and (iiii) reduced expression in rectal cancer. CLCA1 expression was strongly associated
with (B) a different tumor status, (C) lymph node metastasis, (D) Dukes staging, and (E) histological grades. Expression levels of
CLCA1 were quantified via the ratio of positive cells to total cells. Data are presented as means and standard errors of the mean.
CLCA1 indicates chloride channel accessory 1.
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and Ki-67 expression in the primary tumors (P5 .29;
Fig. 3A). Furthermore, we investigated the correlation
between the expression of PTEN and CLCA1 and found
no association between the expression levels of these 2
molecules (P5 .95; Fig. 3B). However, CLCA1 expres-
sion levels correlated strongly and positively with the level
Figure 2. CLCA1 expression levels and disease-free survival for CRC patients. Kaplan-Meier curves of disease-free survival are
shown for CRC patients: (A) different CLCA1 expression (P< .05), (B) tumor status (P< .05), (C) lymph node metastasis (P>.05),
and (D) Ki-67 expression (P> .05). The differences between curves were analyzed with the log-rank test. CLCA1 indicates chloride
channel accessory 1; CRC, colorectal cancer.
Figure 3. Correlation between the expression of CLCA1 and knownprognosticmarkers for colorectal cancer. Expression levels of CLCA1,
Ki-67, E-cad, PTEN, and p53 were analyzed through the percentages of positively staining cells. The correlations of CLCA1 expression
with (A) Ki-67 (n528, R250.18, P5.29), (B) PTEN (n59, R25 –0.02, P5.95), (C) E-cad (n5 12, R250.8, P5.0016), and (D) p53 (n5 15,
R250.78,P5.0007) are shown, and strongpositive correlations between high CLCA1 expression and high E-cad and p53 expression lev-
els are indicated.CLCA1 indicates chloride channel accessory 1; E-cad, E-cadherin; PTEN, phosphatase and tensin homolog.
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of p53 and E-cadherin expression (P< .01; Fig. 3C,D).
The downregulation of E-cadherin at the membrane indi-
cated a poor outcome.15 p53 is a tumor suppressor in
CRC. Mutations of p53 are associated with worse sur-
vival, and normal levels of p53 are required for CRCs to
respond to chemotherapy.16 These data further confirm
that low expression of CLCA1 appears to correlate
strongly with a poor prognosis of CRC.
Confirmation of CLCA1 Expression in CRC With
Microarray Data Sets
To further validate our data, we analyzed the 3 public, in-
dependent microarray data sets from GEO. Our analysis
showed that the expression level of CLCA1 was inhibited
significantly in early CRC specimens (normal vs early
CRC, P< .05; Fig. 4A). In comparison with nonmeta-
static specimens, the expression of CLCA1 was downregu-
lated significantly in metastatic CRC (P< .01; Fig. 4B).
CIN-high showed the worst survival for CRC patients.27
Our results showed that CRC with the CIN-high pheno-
type had lower expression of CLCA1 than CRC with the
CIN-low phenotype (P5 .015; Fig. 4C). Therefore, the
results from these 3 independent microarray sets were
identical to the results from our clinical analysis data.
CLCA1 Regulates the Differentiation of Human
CRC Cells
Culturing to confluence induces the spontaneous differ-
entiation of human colon adenocarcinoma cells (Caco-
2).11,33-35 Using this model, we investigated further the
functional role of CLCA1 in the differentiation of Caco-2
cells. First, we detected the expression of CLCA1 and the
differentiation marker E-cadherin in a confluent culture.
We found that the expression of both CLCA1 and E-
cadherin was increased in a time-dependent manner (Fig.
5A). These data suggest that the expression of CLCA1
may contribute to the spontaneous differentiation of
Caco-2 cells. Next, we used stealth siRNA (siRNACLCA1)
to knock down the expression of CLCA1 in Caco-2 cells.
After 72 hours of transfection, cells were tested for the
expression of CLCA1, ALPI, and E-cadherin by western
blotting. We found that knockdown of CLCA1 inhibited
expression levels of ALPI and E-cadherin significantly
(Fig. 5B).10 These results indicate that CLCA1 expression
plays a key role in the regulation of the spontaneous differ-
entiation of Caco-2 cells.
DISCUSSION
In 2010, 40,695 people in the United Kingdom were diag-
nosed with bowel cancer, and 15,708 died from the disease.
In CRC, one of the important challenges is the accurate
prediction of which patients will experience disease relapse
after surgery and which patients will require and most ben-
efit from adjuvant therapies. At present, the TNM staging
system for tumors is the gold standard for determining the
prognosis of patients with CRC. The staging system is de-
pendent on the extent of local invasion, the degree of
lymph node involvement, and the presence or absence of
distant metastases. However, this system can cause prob-
lems, especially with respect to treatment decisions.36 For
example, the number of paraffin blocks containing tumor
tissue (tumor blocks) will affect directly the likelihood of
Figure 4. Publicly available microarray data sets for validation.
(A) In public microarray data set GSE4107, we analyzed the
expression of CLCA1 in normal colon mucosa and CRC tissues.
The results showed that the expression of CLCA1 was inhibited
significantly in early CRC patients. (B) In the GSE28702 micro-
array gene set, low expression of CLCA1 was associated with
CRC metastasis. (C) The analysis of the GSE30540 microarray
gene set showed that low CLCA1 expression was associated
with CRC with a CIN-high signature, and this indicated signifi-
cantly poorer survival in comparison with a CIN-low signature.
CIN indicates chromosomal instability; CLCA1, chloride channel
accessory 1; CRC, colorectal cancer.
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detecting submucosal, mesocolic, mesorectal, or peritoneal
invasion, and the greater the number of tumor blocks dis-
sected, the higher the expected T stage.36 Hence, additional
prognostic biomarkers are needed urgently for the
improved management of CRC patients.37
The high tissue specificity of transcription of some
CLCAs38 suggested initially that the detection of their
expression in specific tissues might be useful for early di-
agnosis, as a means of molecular staging, and for postoper-
ative surveillance.11 In this study, primary CRC tumors
showed significantly lower expression of CLCA1 in both
membranes and cytoplasm in comparison with the nor-
mal colonic tissues. This may suggest that reduced
CLCA1 expression is a biomarker of malignant cells.
Patients in different stages of disease also show a big dis-
crepancy in survival. Molecules involved in cancer relapse
and prognosis might serve as markers for the early detec-
tion of metastasis and as a measure for therapeutic inter-
vention (eg, N-Myc downstream-regulated gene 2,
E-cadherin, and p53).15,16,18,39 In CRC, CLCA1 and
CLCA4 are downregulated significantly in approximately
80% of patients.11 The loss of expression of both CLCA1
and CLCA4 during tumorigenesis suggests that strong
activation of either might inhibit the survival of tumor
cells.4 Our findings showed that CLCA1 expression was
downregulated significantly in CRC and highly associated
with known high-risk factors such as the tumor status,
lymph node metastasis, Dukes grade, and histologic stag-
ing. Our data suggested that CLCA1 expression also
decreased progressively from good to poor differentiation
and with the progression of tumor stages. Specifically, the
expression of CLCA1 in advanced CRC was decreased
further in comparison with early stages of CRC. This
indicated that the level of CLCA1 expression in primary
CRCmight be associated with its prognosis.
Several molecular prognostic factors, such as p53,
Ki-67, K-ras, and E-cadherin, are being evaluated in CRC
patients,15,16,30,31 and it is still not possible to predict
accurately the probability of recurrence of CRC in
patients after surgery.32 Therefore, it is necessary to find
reliable and sensitive markers that can help us to make
well-informed decisions regarding which patients should
receive chemotherapy and which should not. Here we
have shown that the level of CLCA1 expression is corre-
lated with the expression of known predictors: E-cadherin
and p53. CLCA2 has been reported to be a p53-inducible
inhibitor of cell proliferation and to be downregulated
with tumor progression.1,6 Downregulation of E-
Figure 5. CLCA1 contributes to the differentiation of colorectal cancer cells. Human colon adenocarcinoma cells (Caco-2) were
cultured to become confluent for 10 days. (A) The expression of CLCA1 was upregulated for 4 days in a confluent culture and
lasted for up to 10 days of culturing. The mature epithelial marker E-cad increased in a time-dependent manner. The histogram
shows the relative intensity of E-cad expressed as a ratio with respect to the GAPDH control. (B) Caco-2 cells were transfected
transiently with 150 nM siRNACLCA1 and blotted for CLCA1, E-cad, and ALPI. siRNACLCA1 effectively inhibited CLCA1 and downre-
gulated the expression of E-cad and ALPI. The histogram shows the relative intensity of CLCA1, E-cad, and ALPI expressed as a
ratio with respect to the GAPDH control. Data are presented as means and standard errors of the mean. All results were analyzed
on the basis of 3 independent experiments. ALPI indicates intestinal alkaline phosphatase; CLCA1, chloride channel accessory 1;
Cont, control; E-cad, E-cadherin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; siRNA, small interfering RNA.
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cadherin at the membrane indicates a poorer prognosis.15
These results further support the notion that CLCA1 may
be a tumor suppressor and may be associated with pro-
gressive potential.
Kaplan-Meier survival analysis is defined as the prob-
ability of surviving for a given length of time, and it is used
to compare the fraction of patients living for a certain
amount of time after treatment.40 To further validate our
hypothesis, we used Kaplan-Meier analysis to test the prog-
nostic sensitivity of CLCA1 in CRC. Although we analyzed
a small group of 36 patients, we found that CRC patients
with high CLCA1 expression levels had better DFS than
CRC patients with low CLCA1 expression levels. The tu-
mor stage as a univariate prognostic factor in CRC also cor-
related with the survival time of this group of patients.
Higher CLCA1 expression proved to be correlated with
longer survival for patients with CRC. Extending DFS
means the prevention or delay of recurrence or metastasis,
and this is a clinical benefit. To validate the prognostic
potential of CLCA1, we analyzed the expression of CLCA1
in normal and early CRC, primary CRC and metastases,
and CIN-high and CIN-low phenotypes from 3 independ-
ent microarray data sets. Our results further confirmed that
low expression of CLCA1 correlated with the tumorigene-
sis of CRC, metastasis, and a CIN-high gene signature. In
this respect, our findings indicate that measurements of
CLCA1 expression may help to identify patients at high
risk of a poorer prognosis. Therefore, an assessment of
CLCA1 levels could contribute to an accurate prediction of
the prognosis and recurrence probability of patients after
potentially curative surgery and, consequently, to individu-
alized treatment for each patient.
Recent studies have shown that CLCA1 could
increase cell differentiation through the regulation of the
proliferation-to-differentiation transition.10 CLCA2 also
has been reported to suppress the epithelial-mesenchymal
transition in breast cancer.1 The CLCA1 precursor is
approximately 900 amino acids long with 1 proteolytic
cleavage site after the amino-terminal signal sequence.
Eventually, 2 products of 90 and 30 to 40 kDa play func-
tional roles.3,4,8,9 Using cultured Caco-2 monolayers as a
model, we found that CLCA1 promotes intestinal epithe-
lial differentiation through enhancement of E-cadherin
and ALPI expression (Fig. 5).10 In some tumor types,
including CRC, E-cadherin expression is often downregu-
lated in highly invasive, poorly differentiated carcino-
mas.41,42 Decreased E-cadherin expression through the
inhibition of CLCA1 might block cell differentiation and
increase the likelihood of distant metastasis. Thus, the loss
of expression of CLCA1 appears to be an important step
in tumorigenic progression. Although the clinical role and
therapeutic effect of CLCA1 are still to be investigated,
the current study will continue to improve our under-
standing of the biological profile and behavior of CRC.
In summary, we have shown that aberrant CLCA1
expression is a sign of a poor outcome in CRC. Our data
indicate that low levels of CLCA1 in primary CRC might
be a powerful predictor of disease relapse and prognosis.
Although further prospective studies will be needed to
determine the actual clinical utility of this observation,
our findings indicate that CLCA1 might be a sensitive
prognostic marker for evaluating the recurrence, early me-
tastasis, and prognosis of CRC. Moreover, it might also
be a potential therapeutic target for molecular therapy.
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